echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Procon Health Technology and Hutchison Medical reach clinical cooperation

    Procon Health Technology and Hutchison Medical reach clinical cooperation

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    On February 23, Convalife announced that it has reached a clinical cooperation with Hutchison Pharmaceuticals to evaluate the high selection of PARP inhibitors Mefurpiride and Hutchison Pharmaceuticals with "best-in-class" potential for approval for listing The safety and tolerability of Fruquintinib combined with the treatment of solid tumors.


    Mefuparib (CVL218) is a polyadenosine diphosphate ribose polymerase (PARP) inhibitor.


    Fruquintinib Capsules (Ayute) is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.